652. Ceftazidime-avibactam Alone or as Combination Therapy? Multicenter Retrospective Cohort Analysis of Clinical Outcomes in Patients with Carbapenem-resistant Gram-negative Infection

BACKGROUND: Ceftazidime-avibactam (caz-avi), a novel β-lactam/β-lactamase inhibitor, is commonly utilized for carbapenem-resistant gram-negative infections (CR-GNI). However, the benefits vs risks of combining caz-avi with other agents are unclear. METHODS: In this retrospective cohort study, inpati...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishuk, Ahmed Ullah, Strich, Jeffrey R, Warner, Sarah, Sun, Junfeng, Malik, Seidu, Lawandi, Alexander, Kondo, Maiko, Satlin, Michael J, Chandorkar, Aditya, Heil, Emily L, Morales, Megan K, Mathur, Anisha, Timpone, Joseph, Wooten, Darcy, Sweeney, Daniel, Pan, Jonathan, Raybould, Jillian, Bonne, Stephanie, Colindres, Roberto, Boucher, Helen W, Buckman, Sara, Furukawa, Daisuke, Uslan, Daniel, Hohmann, Samuel F, Kadri, Sameer S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752154/
http://dx.doi.org/10.1093/ofid/ofac492.704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752154/
http://dx.doi.org/10.1093/ofid/ofac492.704

Ejemplares similares